Medicenna Presents Compelling Results from the ABILITY-1 Clinical Trial at the 2025 AACR Annual MeetingTen (10) patients have achieved an objective response (5 confirmed) when treated with MDNA11 alone or in combination with KEYTRUDA® (pembrolizumab) – all responders had advanced and/or metastatic cancers with resistance to immune checkpoint inhibitors (ICI) or with historically low responses to ICI
